This session will update attendees on the current status of the 340B drug discount program, including ongoing litigation relating to manufacturer contract pharmacy limits and the potential implications of Loper Bright, developments with the administrative dispute resolution process, state legislative initiatives, and potential emerging mechanisms to identify ineligible and duplicate 340B discounts, including under the Inflation Reduction Act’s price regulation programs.

This is Part 1 of a six-part series. Part 2, How the toughened up, amended Fed. R. Evid. 702 has been faring is taking place on November 12, 2024, Part 3, New Rule 16.1 on MDLs is taking place on November 13, 2024, Part 4, PFAS Litigation in the MedTech Industry: Key Cases and Emerging Trends is taking place on November 13, 2024, Part 5, Product Liability in Europe: Understanding and Planning for the EU’s Recent Complainant-Friendly Shift is taking place on November 14, 2024, and Part 6, The New Frontier: AI in Product Liability Law is taking place on November 14, 2024.

Each of these programs are presumptively approved for 1.0 CLE credit in California, Connecticut, Illinois, New Jersey, New York, Pennsylvania, Texas, and West Virginia. Applications for CLE credit will be filed in Delaware, Florida, Ohio, and Virginia. Attendees who are licensed in other jurisdictions will receive a uniform certificate of attendance but Reed Smith only provides credit for the states listed. Please allow 4-6 weeks after the program to receive a certificate of attendance.